RxDoctor Payments Data

Chunguang Chen, MD

Cardiovascular Disease · Newark, NJNPI 1093862138

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (45.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 64.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $8,315 and has fallen 62.4% since, to $3,124 in 2025.

$16,546in general payments, 2019–2025

Across 92 payments — averaging $179.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$11K
  • Abbott$4K
  • Ancora Heart, Inc.$924
  • Irhythm Technologies, Inc.$416
  • Medtronic$140
  • Abiomed$122
  • plus $107 from 2 others
$11,143in research payments, 2019–2025

Across 2 payments — averaging $5571.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$11K

What the payments were for

  • Consulting fees$6,30038%
  • Travel & lodging$7,51945%
  • Food & beverage$2,72716%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,546 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey →

Medicare billing

Part B allowed, 2024
$169,884
Medicare patients
1,210
Services billed
2,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Newark

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →